65756 Federal Register / Vol. 72, No. 225 / Friday, November 23, 2007 / Notices 

inhibitors. These NNRTIs are highly 

specific for HIV–1 RT and do not inhibit 

normal cellular polymerases, resulting 

in lower cytotoxicity and fewer side 

effects that the nucleoside analogues, 

such as AZT. This novel class of 

compounds could significantly improve 

the treatment of HIV by increasing 

compliance with therapy. 

Inventors: Christopher A. Michejda, 

Marshall Morningstar, Thomas Roth 

(NCI). 

Patent Status: U.S. Patent No. 

6,369,235 issued 09 Apr 2002 (HHS 

Reference No. E–076–1997/1–US–01); 

U.S. Patent No. 6,894,068 issued 17 May 

2005 (HHS Reference No. E–076–1997/ 

1–US–02). 

Licensing Contact: Sally Hu, PhD., 

MBA; 301/435–5606; hus@mail.nih.gov. 

Dated: November 9, 2007. 

Steven M. Ferguson, 

Director, Division of Technology Development 

and Transfer, Office of Technology Transfer, 

National Institutes of Health. 

[FR Doc. E7–22821 Filed 11–21–07; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

Public Teleconference Regarding 

Licensing and Collaborative Research 

Opportunities for: ‘‘Brother of the 

Regulator of Imprinted Sites’’ (BORIS): 

A Novel Protein That Can Be Used for 

Diagnosis and as a Therapeutic Target 

for the Treatment of Several Cancers; 

Dr. Victor Lobanenkov et al. (NIAID) 

AGENCY: National Institutes of Health, 

Public Health Service, HHS. 

ACTION: Notice. 

Technology Summary 

The technology describes the 

discovery of a novel gene encoding the 

DNA-binding factor, ‘‘Brother of the 

Regulator of Imprinted Sites’’, BORIS, 

related to the unique, evolutionarily 

conserved, CTCF factor involved in 

regulation of genomic imprinting and 

cancer. Furthermore, it describes several 

splice variants of BORIS that translate 

into different proteins and antibodies of 

BORIS that can be used for diagnosis 

and treatment of cancer. 

Technology Description 

A very recent finding is that protein 

CTCF (expressed in all somatic tissues) 

binds, in a methylation-dependent 

manner, to the imprinting control 

regions thus allowing somatic cells to 

distinguish functionally maternal from 

paternal alleles. The new factor, BORIS, 

shares with CTCF the same spectrum of 

DNA sequence specificity and it is 

normally expressed only in germ cells of 

human gonads (when patterns of gene 

imprinting are re-established), but not in 

CTCF-expressing somatic cells. 

Additionally, since cell-growth 

controlling CTCF has properties of a 

tumor suppressor gene, abnormal 

activation of BORIS upon cancerous 

transformation of somatic cells results 

in competition with the normal function 

of CTCF, thereby promoting tumor 

growth. The inventors found that 

antibodies against BORIS are present 

and can be detected in human blood 

serum taken from patients with cancer 

but not from healthy donors. 

Additionally, 14 new alternative splice 

forms of the BORIS polypeptide have 

been identified which show specificity 

to specific cancers, suggesting that 

circulating antibodies for specific 

BORIS splice variants in cancer patients 

can be associated with specific types or 

stages of malignant tumors. 

Therefore, BORIS can be used in both 

diagnostic and therapeutic arenas: First, 

mutations in BORIS genomic locus or 

detection of encoded by the BORIS 

locus mRNAs or polypeptides expressed 

in any tissue besides normal gonads 

may be indicative of a pre-cancerous or 

cancerous state thus serving a diagnostic 

and/or prognostic purpose; and, second, 

targeting of abnormally activated BORIS 

should serve as a novel therapeutic 

approach to treat cancer. 

BORIS Technology Can Have Three 

Major Applications 

1. BORIS can be used as a therapeutic 

target for anti-cancer treatments. 

2. BORIS expression can serve as a 

diagnostic marker for specific cancers 

other than testis. 

3. Detection of antibodies against 

BORIS in blood serum samples can also 

be used as an indicator of pre-cancerous 

or cancerous condition existing. 

Competitive Advantage of Our 

Technology 

Cancer/testis (CT) genes, 

predominantly expressed in the testis 

(germ cells) and generally not in other 

normal tissues, are aberrantly expressed 

in human cancers. This highly restricted 

expression provides a unique 

opportunity to use these CT genes for 

diagnostics, immunotherapeutic, or 

other targeted therapies. BORIS is a 

newly described CT gene shown to be 

expressed in several cancers including 

lung, brain, uterine and endometrial 

among others and thus can be used as 

a novel diagnostic and therapeutic 

target. 

Patent Estate 

This technology consists of the 

following patents and patent 

applications: 

1. U.S. Patent Application No. 10/ 

505,377 filed October 20, 2004 and all 

foreign counterparts [E–227–2001/0–

US–03]; 

2. U.S. Patent Application No. 11/ 

575,732 filed March 21, 2007 and all 

foreign counterparts [E–241–2004/0–

US–04]; and 

3. PCT Application No. PCT/US2007/ 

7728 filed August 30, 2007 [E–117–

2006/0–PCT–02] 

Next Step: Teleconference 

There will be a teleconference where 

the principal investigator will explain 

this technology. Licensing and 

collaborative research opportunities will 

also be discussed. If you are interested 

in participating in this teleconference 

please call or e-mail Mojdeh Bahar; 

(301) 435–2950; baharm@mail.nih.gov. 

OTT will then e-mail you the date, time 

and number for the teleconference. 

Dated: November 9, 2007. 

Steven M. Ferguson, 

Director, Division of Technology Development 

and Transfer, Office of Technology Transfer, 

National Institutes of Health. 

[FR Doc. E7–22820 Filed 11–21–07; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Institute of Environmental 

Health Sciences; Notice of Closed 

Meeting 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended (5 U.S.C. Appendix 2), notice 

is hereby given of the following 

meeting. 

The meeting will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6). Title 5 U.S.C., 

as amended. The grant applications and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: National Institute of 

Environmental Health Sciences Special 

Emphasis Panel, Genetic Environmental 

Training. 

Date: November 27, 2007. 

Time: 8:30 a.m. to 5 p.m. 

mstockstill on PROD1PC66 with NOTICES

Federal Register / Vol. 72, No. 225 / Friday, November 23, 2007 / Notices 65757 

Agenda: To review and evaluate grant 

applications. 

Place: Sheraton Imperial Hotel RTP, 

Sheraton Imperial Hotel, 4700 Emperor Blvd, 

Durham, NC 27703. 

Contact Person: Leroy Worth, Scientific 

Review Administrator, Scientific Review 

Branch, Division of Extramural Research and 

Training, Nat. Institute of Environmental 

Health Sciences, P.O. Box 12233, MD EC–30/ 

Room 3171, Research Triangle Park, NC 

27709, 919/541–0670, worth@niehs.nih.gov. 

This notice is being published less than 15 

days prior to the meeting due to the timing 

limitations imposed by the review and 

funding cycle. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.115, Biometry and Risk 

Estimation—Health Risks from 

Environmental Exposures; 93.142, NIEHS 

Hazardous Waste Worker Health and Safety 

Training; 93.143, NIEHS Superfund 

Hazardous Substances—Basic Research and 

Education; 93.894, Resources and Manpower 

Development in the Environmental Health 

Sciences; 93.113, Biological Response to 

Environmental Health Hazards; 93.114, 

Applied Toxicological Research and Testing, 

National Institutes of Health, HHS) 

Dated: November 14, 2007. 

Jennifer Spaeth, 

Director, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 07–5779 Filed 11–21–07; 8:45 am] 

BILLING CODE 4140–01–M 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

Center for Scientific Review; Notice of 

Closed Meeting 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended (5 U.S.C. Appendix 2), notice 

is hereby given of the following 

meeting. 

The meeting will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended. The grant applications and 

the discussions could disclose 

confidential trade secrets of commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: Center for Scientific 

Review Special Emphasis Panel, 

Endocrinology and Metabolism. 

Date: December 5, 2007. 

Time: 10 a.m. to 12 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 6701 

Rockledge Drive, Bethesda, MD 20892, 

(Telephone Conference Call). 

Contact Person: Ann A. Jerkins, PhD, 

Scientific Review Administrator, Center for 

Scientific Review, National Institutes of 

Health, 6701 Rockledge Drive, Room 6154, 

MSC 7892, Bethesda, MD 20892, 301–435–

4514, jerkinsa@csr.nih.gov. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.306, Comparative Medicine; 

93.333, Clinical Research, 93.306, 93.333, 

93.337, 93.393–93.396, 93.837–93.844, 

93.846–93.878, 93.892, 93.893 National 

Institutes of Health, HHS) 

Dated: November 14, 2007. 

Jennifer Spaeth, 

Director, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 07–5778 Filed 11–21–07; 8:45 am] 

BILLING CODE 4140–01–M 

DEPARTMENT OF HOMELAND 

SECURITY 

National Protection and Programs 

Directorate, Office of Infrastructure 

Protection, Submission for Review 

Chemical Security Assessment Tool 

(CSAT) Information Collection 1670–

0007 

AGENCY: National Protection and 

Programs Directorate, DHS. 

ACTION: 60-Day Notice and request for 

comments: Revision of an existing 

information collection request 1670–

0007, DHS Forms 9010, 9002, 9007, 

9012, and 9015. 

SUMMARY: The Department of Homeland 

Security, Office of the Under Secretary 

for National Protection and Programs 

Directorate, Office of Infrastructure 

Protection, Chemical Security 

Compliance Division (CSCD) has 

submitted the following information 

collection request (ICR) to the Office of 

Management and Budget (OMB) for 

review and clearance in accordance 

with the Paperwork Reduction Act of 

1995. 

DATES: Comments are encouraged and 

will be accepted until January 22, 2008. 

This process is conducted in accordance 

with 5 CFR 1320.1. 

ADDRESSES: Comments and questions 

about this Information Collection 

Request should be forwarded to the 

Office of Infrastructure Protection, Attn: 

Matthew Bettridge, Department of 

Homeland Security, NPPD/OIP/CSCD 

Mail Stop 8100, DHS, Washington, DC 

20528. 

FOR FURTHER INFORMATION CONTACT: 

Office of Infrastructure Protection, Attn: 

Matthew Bettridge, Department of 

Homeland Security, NPPD/OIP/CSCD 

Mail Stop 8100, DHS, Washington, DC 

20528. 

SUPPLEMENTARY INFORMATION: Section 

550 of the Department of Homeland 

Security Appropriations Act of 2007, 

Pub. L. 109–295 (Section 550), directed 

the Department of Homeland Security to 

promulgate and enforce regulations to 

enhance the security of the nation’s high 

risk chemical facilities. On April 9, 

2007, the Department issued an Interim 

Final Rule, implementing this statutory 

mandate. (72 FR 17688). Section 550 

requires a risk-based approach to 

security. To facilitate this approach, the 

Department is employing a risk 

assessment methodology known as the 

Chemical Security Assessment Tool 

(CSAT). The CSAT is a series of public 

web-based computer applications: Help 

Desk, User Registration, Top-Screen, 

Security Vulnerability Assessment, Site 

Security Plan, and Chemical-terrorism 

Vulnerability Information (CVI) 

Authorization. All information collected 

supports the Department’s effort to 

reduce the risk of a successful terrorist 

attack against chemical facilities. These 

CSAT collections either directly or 

indirectly support the identification of 

high risk facilities, the determination of 

the risk tiers of the facilities, the review 

and approval of assessments and plans 

for security measures at the facilities, 

and/or the protection of Chemicalterrorism Vulnerability Information that 

would, if disclosed, substantially assist 

terrorists in planning and targeting the 

facilities. 

The Office of Management and Budget 

is particularly interested in comments 

which: 

1. Evaluate whether the proposed 

collection of information is necessary 

for the proper performance of the 

functions of the agency, including 

whether the information will have 

practical utility; 

2. Evaluate the accuracy of the 

agency’s estimate of the burden of the 

proposed collection of information, 

including the validity of the 

methodology and assumptions used; 

3. Enhance the quality, utility, and 

clarity of the information to be 

collected; and 

4. Minimize the burden of the 

collection of information on those who 

are to respond, including through the 

use of appropriate automated, 

electronic, mechanical, or other 

technological collection techniques or 

other forms of information technology, 

e.g., permitting electronic submissions 

of responses. 

Analysis 

Agency: Department of Homeland 

Security, Office of the Under Secretary 

for National Protection and Programs 

Directorate, Office of Infrastructure 

mstockstill on PROD1PC66 with NOTICES